"What Weyland is doing is profiting from the market's tendency to overreact to events that are not fundamental changes in the company. As legendary investor George Soros has noted, in the short term the financial markets are "chaotic." After good news from bio tech, the stock will shoot up. Invariably, it settles back down again. Then savvy stock pickers can profit from buying shares of companies such as Vivus, Amarin and Depomed when they rebound"